Cargando…

Ivermectin in COVID-19. Argumentun ad ignorantiam?()

Detalles Bibliográficos
Autor principal:	Carlosama-Rosero, Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI). 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366964/ https://www.ncbi.nlm.nih.gov/pubmed/32616298 http://dx.doi.org/10.1016/j.rceng.2020.06.003

Ejemplares similares

Ivermectina en COVID-19. ¿Argumentum ad ignorantiam?
por: Carlosama-Rosero, Y.
Publicado: (2020)

Reply to: Ivermectin in COVID-19. Argumentum ad ignorantiam?()
por: López Reboiro, M.L., et al.
Publicado: (2020)

COVID-19 and Argumentum ad ignorantiam or “not everything goes”()
por: López Reboiro, M.L., et al.
Publicado: (2020)

Réplica: Ivermectina en COVID-19. ¿Argumentum ad ignorantiam?
por: López Reboiro, M.L., et al.
Publicado: (2020)

COVID-19 y Argumentum ad ignorantiam o «no todo vale»
por: López Reboiro, M.L., et al.
Publicado: (2020)

Standard Dose Ivermectin for COVID-19
por: Buonfrate, Dora, et al.
Publicado: (2021)

Toxic Effects from Ivermectin Use Associated with Prevention and Treatment of Covid-19
por: Temple, Courtney, et al.
Publicado: (2021)

Successful treatment of tocilizumab and ivermectin for a patient with ARDS due to COVID-19
por: Chuang, Tzu-Yi, et al.
Publicado: (2021)

Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients
por: Okumuş, Nurullah, et al.
Publicado: (2021)

Response to Letter Regarding Article, “Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial”
por: Shahbaznejad, Leila, et al.
Publicado: (2021)

Ivermectin Should Not Be Recommended to Treat Severe Acute Respiratory Syndrome 2 Infection
por: Boven, A G, et al.
Publicado: (2021)

Ivermectin for Coronavirus Disease 2019: Yet to Be Well Evaluated Before Clinical Use
por: Hagiya, Hideharu, et al.
Publicado: (2021)

Ivermectin and COVID-19
por: Wiwanitkit, Viroj
Publicado: (2021)

Co-infections: testing macrolides for added benefit in patients with COVID-19
por: Sterenczak, Katharina Anna, et al.
Publicado: (2020)

Remarks About Retrospective Analysis of Ivermectin Effectiveness on Coronavirus Disease 2019 (ICON Study)
por: Ortega-Guillén, Eduardo, et al.
Publicado: (2021)

Lymphohistocytic myocarditis after Ad26.COV2.S viral vector COVID-19 vaccination
por: Ujueta, Francisco, et al.
Publicado: (2021)

Emergence of COVID-19 variants among ChAdOx1 nCoV-19 (recombinant) vaccine recipients
por: Vaishya, Raju, et al.
Publicado: (2021)

Comparison of S1 antibody titers between BNT162b2 and ChAdOx1 COVID-19 vaccination in cancer patients
por: van Dam, P.A., et al.
Publicado: (2022)

COVID-19: The Ivermectin African Enigma
por: Guerrero, Rodrigo, et al.
Publicado: (2020)

Ivermectin for preventing and treating COVID‐19
por: Popp, Maria, et al.
Publicado: (2021)

The Effect of Ivermectin on Cases of COVID-19()
por: Annie, Frank H., et al.
Publicado: (2022)

Ivermectin for preventing and treating COVID‐19
por: Popp, Maria, et al.
Publicado: (2022)

Is Ivermectin Effective in Treating COVID-19?
por: Yang, Shuangshuang, et al.
Publicado: (2022)

The Use of Ivermectin in the Treatment of COVID-19
por: Shukla, Ajay Kumar, et al.
Publicado: (2023)

COVID-19 vaccine-induced T-cell responses in patients with rheumatoid arthritis: preferential induction by ChAdOx1
por: Saleem, Benazir, et al.
Publicado: (2022)

Microbiome-Based Hypothesis on Ivermectin’s Mechanism in COVID-19: Ivermectin Feeds Bifidobacteria to Boost Immunity
por: Hazan, Sabine
Publicado: (2022)

ROX monitoring in critical COVID-19 patients treated with high flow oxygen: A real added value compared to the respiratory rate?
por: Garnier, M., et al.
Publicado: (2021)

Ivermectin: potential candidate for the treatment of Covid 19
por: Gupta, Dhyuti, et al.
Publicado: (2020)

Ivermectin: Panacea or true promise for COVID-19
por: Heimfarth, Luana, et al.
Publicado: (2020)

Adverse drug reactions and ivermectin in COVID-19
por: Montastruc, Jean-Louis
Publicado: (2022)

Ivermectin as a potential treatment for COVID-19?
por: Chosidow, Olivier, et al.
Publicado: (2021)

Ivermectin for COVID-19: Concerns during pregnancy
por: Wise, L. David, et al.
Publicado: (2022)

Retraction: Microbiome-based hypothesis on Ivermectin's mechanism in COVID-19: Ivermectin feeds bifidobacteria to boost immunity
Publicado: (2023)

ChAdOx1 COVID-19 Vaccine-Associated Erythema Multiforme Major and Erythema Multiforme-Like Vasculitis: A Tale of Two Cases
por: Mehta, Nikhil, et al.
Publicado: (2022)

ChAdOx1 nCoV-19 vaccine for SARS-CoV-2
por: Lodge, Archie
Publicado: (2020)

ChAdOx1 nCoV-19 vaccine for SARS-CoV-2
por: Chauhan, Anil, et al.
Publicado: (2020)

Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination
por: Normark, Johan, et al.
Publicado: (2021)

Expression of concern: Microbiome-based hypothesis on Ivermectin's mechanism in COVID-19: Ivermectin feeds bifidobacteria to boost immunity
Publicado: (2023)

Takotsubo syndrome – adding pieces to a complex puzzle
por: Manginas, Athanassios, et al.
Publicado: (2017)

Ivermectin in COVID-19: What do we know?
por: Pandey, Sanjay, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_843ks1hdakvm07tsq2cmht65cm